- ISIN
- US05337M1045
- CUSIP
- 05337M104
- Sector
- Healthcare
- IPO Date
- Jun 7, 1996
Highlights
- Market Cap
- $2.19B
- Enterprise Value
- $2.15B
- EPS (TTM)
- -$0.00
- Total Revenue (TTM)
- $248.52M
- Gross Profit (TTM)
- $234.76M
- EBITDA (TTM)
- $10.13M
- Year Range
- $8.52 - $23.57
- ROA (TTM)
- -0.14%
- ROE (TTM)
- -0.28%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AVDL Performance Chart
Loading charts...
Returns By Period
Avadel Pharmaceuticals plc
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
AVDL Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.00% | 0.42% | 0.42% | ||||||||||
| 2025 | -24.83% | 0.13% | -1.01% | 13.54% | 2.47% | -2.85% | 18.76% | 40.44% | 3.46% | 23.71% | 13.76% | 0.28% | 105.04% |
| 2024 | 1.91% | -11.19% | 32.16% | 7.52% | -12.17% | -11.85% | 16.22% | -7.16% | -13.55% | 17.96% | -28.51% | -4.97% | -25.57% |
| 2023 | 5.10% | 32.23% | -7.94% | 14.41% | 32.16% | 18.99% | -14.44% | -4.18% | -23.76% | -4.27% | 17.04% | 22.36% | 97.21% |
| 2022 | -25.50% | 33.89% | -15.26% | -26.79% | -55.80% | 10.41% | 93.85% | 40.38% | -24.55% | 31.54% | 39.15% | -21.92% | -11.39% |
| 2021 | 9.28% | 10.14% | 12.44% | -17.04% | 2.53% | -12.48% | 15.45% | 6.69% | 18.21% | -0.92% | -7.72% | -9.82% | 20.96% |
Benchmark Metrics
Avadel Pharmaceuticals plc has an annualized alpha of 37.68%, beta of 0.73, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 10, 1996.
- This stock participated in 107.89% of S&P 500 Index downside but only 81.32% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 37.68%
- Beta
- 0.73
- R²
- 0.03
- Upside Capture
- 81.32%
- Downside Capture
- 107.89%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Avadel Pharmaceuticals plc (AVDL) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Avadel Pharmaceuticals plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Avadel Pharmaceuticals plc was 97.50%, occurring on May 26, 2022. The portfolio has not yet recovered.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -97.50%May 2022 | 18y 8mo | — | 22y 8moSep 2003 - now |
Dot-com crash2000–2002 | -92.17%Oct 2001 | 5y 3mo | 1y 8mo | 6y 11moJun 1996 - Jun 2003 |
2003 bear market2003 | -26.12%Aug 2003 | 11d | 19d | 1moJul 2003 - Aug 2003 |
2003 pullback2003 | -9.84%Jun 2003 | 4d | 13d | 17dJun 2003 - Jun 2003 |
2003 pullback2003 | -6.59%Jul 2003 | 1d | 2d | 3dJun 2003 - Jul 2003 |
Drawdown Indicators
| AVDL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | 0.00% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.72% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Avadel Pharmaceuticals plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Avadel Pharmaceuticals plc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AVDL relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AVDL has a P/S ratio of 8.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AVDL in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AVDL has a P/B value of 22.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AVDL
Add Avadel Pharmaceuticals plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AVDL